Dextran is a bacterial polysaccharide which is being increasingly used as a plasma substitute (1-4). Dextran molecules frequently have a molecular weight of several million, and consist of long branched chains of glucose units. For clinical use these large molecules are broken down artificially to an average molecular weight of 70,000. In the body, the larger molecular aggregates are further broken down and excreted as smaller fractions having (approximate) molecular weights less than 20,000, or are slowly metabolized.Dextran has been reported to induce diuresis regularly in patients with the nephrotic syndrome (5, 6). In addition to determining the clinical value of dextran, the intravenous infusion of hyperoncotic (12 per cent) dextran in water was used as an approach to the study of the following questions: 1) Effect of increased plasma volume on glomerular filtration rate;2) The relation of plasma volume, serum albumin concentration, and glomerular filtration rate to the glomerular permeability to albumin;3) The effect of increased post-glomerular colloid osmotic pressure on tubular reabsorption of water and solutes;4) The nature of the dextran-induced diuresis.
METHODNephrotic children who showed no clinical evidence of renal failure were selected (i.e., no concomitant acidosis, azotemia and anemia). The children were recumbent during the study period. Infusions were administered